Patents Examined by Celeste A Roney
  • Patent number: 12029814
    Abstract: Compound formulations and methods for preventing or treating upper respiratory virus infections, such as influenza, respiratory syncytia virus (RSV), SARS, and SARS-COV-2, in human and animal species are disclosed. The compounds may exhibit antiviral, antimicrobial, anti-inflammatory, or cytoprotective activities. Liquid formulations comprising one or more compounds may be administered into the outer canal of the ear for delivery to the nasal and oral cavities, nasopharynx, posterior pharynx and laryngopharynx, the primary sites of upper respiratory infections, located across the tympanic membrane (or eardrum) and eustachian tube, of the individuals infected with one or more upper respiratory viruses or other pathogens. Methods to facilitate trans-tympanic membrane translocation of the compounds by thermal, electrical or electromagnetic impulse, manual or mechanical muscle contraction or stimulation of muscles, nerves or tissues proximate to the eardrum are disclosed.
    Type: Grant
    Filed: October 17, 2023
    Date of Patent: July 9, 2024
    Inventors: Subhash Dhawan, Yashi Dhawan
  • Patent number: 12023402
    Abstract: Described herein are oral care compositions, comprising a peroxydone complex, a dispersant, and a polyvinylpyrrolidone copolymer structure-building agent.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: July 2, 2024
    Assignee: Colgate-Palmolive Company
    Inventors: Shaotang Yuan, Guofeng Xu, Robert Dicosimo, Sharon Haynie
  • Patent number: 12023311
    Abstract: There is provided herein a pharmaceutical formulation having one or more component comprising valproic acid (VPA) and/or a pharmaceutically acceptable salt thereof; and one or more secondary acid, and optionally comprising one or more pharmaceutically acceptable excipient. There is also provided uses of such formulations.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: July 2, 2024
    Assignee: Cereno Scientific AB
    Inventors: Nils Ove Gustafsson, Hans Roger Marcus Martensson, Niklas Bergh, Jonas Faijerson Saljo, Sverker Jern
  • Patent number: 12012391
    Abstract: A 9-(2-hydroxyquinoline-3-yl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: February 7, 2024
    Date of Patent: June 18, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 12005065
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: June 11, 2024
    Assignee: Spruce Biosciences, Inc.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Patent number: 11999653
    Abstract: Methods of making a bioactive glass fiber include forming a melt of a glass composition including: 50 to 70% SiO2; 0.1 to 10% Al2O3, 5 to 30% Na2O, 0.1 to 15% K2O, 0.1 to 15% MgO, 0.1 to 20% CaO, and 5 to 10% P2O5, based on a 100 wt % of the glass composition. The melt has a viscosity of from 200 Poise to 2,000 Poise. Methods include drawing the melt into a drawn glass fiber. Bioactive glass compositions include: 60 to 70% SiO2; 15 to 30% Na2O, 5 to 15% K2O, 1 to 10% CaO, and 5 to 10% P2O5, based on a 100 wt % of the glass composition.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: June 4, 2024
    Assignee: CORNING INCORPORATED
    Inventors: Huayun Deng, Qiang Fu, John Christopher Mauro, Michael Joshua Snyder
  • Patent number: 11998571
    Abstract: Disclosed herein is a pharmaceutical composition comprising at least one selected from the group consisting of a stem cell-conditioned medium and an exosome isolated therefrom as an active ingredient for prevention or treatment of an ocular disease. Containing exosomes, growth factors and neurotrophic factors at high levels and functioning to: promote retinal cell proliferation and wound recovery; protect retinal cells against oxidative stress or hypoxia; lower the increased intraocular pressure and restore the atrophy of the retinal layer and the retinal ganglion cell layer to normal levels in the glaucoma animal model; and have a protective effect on retinal ganglion cells and nerve cells, the stem cell-conditioned medium according to the present disclosure can find advantageous applications in the therapy of an ocular disease.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: June 4, 2024
    Assignee: DESIGNED CELLS CO., LTD.
    Inventors: Yun Bae Kim, Ehn Kyoung Choi, Tae Myoung Kim
  • Patent number: 11998640
    Abstract: Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: June 4, 2024
    Assignees: Park Therapeutics, Inc., Enteris Biopharma, Inc.
    Inventors: James P. Gilligan, George R. Maurer, Aniruddha M. Railkar, Phillip Bauer, Thomas A. Daggs, Paul P. Shields
  • Patent number: 11992557
    Abstract: Pharmaceutical compositions comprising at least one lipid-based particle encapsulating a proteolytic enzyme and a pharmaceutically acceptable carrier, wherein the proteolytic enzyme comprises at least 75% proteolytically active enzyme are provided. Methods of using same and producing same are also provided.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: May 28, 2024
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Avi Schroeder, Assaf Zinger
  • Patent number: 11992553
    Abstract: A method of preparing spray dried particles for inhalation comprising providing: (i) an aqueous liquid composition including the alginate oligomer and an aqueous liquid composition including an anti-adherent compound, or (ii) an aqueous liquid composition including the alginate oligomer and an anti-adherent compound; providing an organic liquid composition including a phospholipid; combining a volume of the organic liquid composition with a volume of the aqueous liquid composition, wherein the total volume of the organic liquid composition is smaller than the total volume of the aqueous liquid composition with which it is combined, and wherein the total volume of aqueous liquid composition and said total volume of organic liquid composition are sufficient to provide a combination; homogenizing the combination to form an organic-in-aqueous liquid emulsion for spray drying; and spray drying the organic-in-aqueous liquid emulsion to form the spray dried particles for inhalation.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: May 28, 2024
    Assignee: AlgiPharma AS
    Inventors: Bildad Nyambura, Anand Bakle, Arne Dessen
  • Patent number: 11980636
    Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: May 14, 2024
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Stefan Faderl
  • Patent number: 11969477
    Abstract: Disclosed is the use of a gold cluster or a gold cluster-containing substance in the preparation of a drug for preventing and/or treating glaucoma.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: April 30, 2024
    Assignee: Shenzhen Profound-View Pharma Tech Co., Ltd
    Inventor: Taolei Sun
  • Patent number: 11964026
    Abstract: Disclosed are particles for delivering cytokinese, such as IL-12, for the treatment of cancer. The particles comprise cytokines non-covalently bound to liposomes, where the liposomes are coated with polyelectrolytes.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: April 23, 2024
    Assignee: Massachusetts Institute of Technology
    Inventors: Antonio Eric Barberio, Santiago Correa Echavarria, Mariane Bandeira Melo, Talar Tokatlian, Erik Christopher Dreaden, Paula T. Hammond, Darrell J. Irvine
  • Patent number: 11957653
    Abstract: The present invention is directed to compositions comprising N-Acetyl Methyl GABA, methods of preparing N-Acetyl Methyl GABA and compositions including N-Acetyl Methyl GABA, and methods of using N-Acetyl Methyl GABA for instance to improve sleep and control anxiety.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: April 16, 2024
    Assignee: MBI Distributing
    Inventor: Ned L. Jensen
  • Patent number: 11957705
    Abstract: Provided herein are methods for the prevention and treatment of cardiovascular diseases and disorders in a subject diagnosed as having suffered a cerebrovascular injury by administering agents that contain or induce the expression of microRNA-126.
    Type: Grant
    Filed: February 24, 2023
    Date of Patent: April 16, 2024
    Assignee: Henry Ford Health System
    Inventors: Jieli Chen, Michael Chopp
  • Patent number: 11958827
    Abstract: A 9-(2-hydroxyquinoline-3-yl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 7, 2023
    Date of Patent: April 16, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11957782
    Abstract: A tooth paste composition comprising black cumin oil (Nigella sativa) and fluoride-doped bioactive glass, zinc oxide, and/or titanium oxide is disclosed.
    Type: Grant
    Filed: June 16, 2023
    Date of Patent: April 16, 2024
    Assignee: Imam Abdulrahman Bin Faisal University
    Inventor: Abdul Samad Khan
  • Patent number: 11944694
    Abstract: Oral care compositions and/or unit-dose oral care compositions comprising a high level of surfactant. Oral care compositions and/or unit-dose oral care compositions with a high foaming efficiency. Oral care compositions and/or unit-dose oral care compositions with one or more web forming materials, one or more surfactants, and a sugar alcohol.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: April 2, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Jeanette Marie Swartz, Arif Ali Baig, Gregory Charles Gordon, Min Mao, Melissa Cherie Payne, Holly Balasubramanian Rauckhorst, Paul Albert Sagel, Paul Dennis Trokhan, Brian Patrick Croll, Dinah Achola Nyangiro
  • Patent number: 11938220
    Abstract: Provided is an anesthetic composition for locally administering a local anesthetic agent to a subject in need thereof. The anesthetic composition has a lipid based complex prepared by hydrating a lipid cake containing a local anesthetic agent and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more robust for large-scale manufacture and for providing a high molar ratio of local anesthetic agent to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.
    Type: Grant
    Filed: March 30, 2019
    Date of Patent: March 26, 2024
    Assignees: Taiwan Liposome Co., Ltd, TLC Biopharmaceuticals, Inc.
    Inventors: Keelung Hong, Yun-Long Tseng, Chun-Yen Lai, Wan-Ni Yu, Hao-Wen Kao, Yi-Yu Lin
  • Patent number: 11931459
    Abstract: In some embodiments provided herein is a method of treating pain, the method comprising administering to the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: March 19, 2024
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventor: Roy Winston